ANI Pharmaceuticals Inc (ANIP) stock
ANIPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 15/3054% below fair value
$71.44+0.38 (+0.53%)
Close on Nov 13, 2026Market cap $1.64BP/E 13.5Yield –
ANI Pharmaceuticals gross margin
Gross margin is gross profit as a percentage of revenue.
ANI Pharmaceuticals's gross margin for the twelve months ending Sep 30, 2026 was 61.1%. For fiscal 2025 it was 61.4%, against 59.3% the year before. The highest annual figure on record is 83.4% in fiscal 2015.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 61.4% | +2.1 |
| FY2024 | Dec 31, 2024 | 59.3% | −3.4 |
| FY2023 | Dec 31, 2023 | 62.7% | +6.6 |
| FY2022 | Dec 31, 2022 | 56.1% | +2.7 |
| FY2021 | Dec 31, 2021 | 53.5% | −4.7 |
| FY2020 | Dec 31, 2020 | 58.2% | −11.2 |
| FY2019 | Dec 31, 2019 | 69.4% | +5.7 |
| FY2018 | Dec 31, 2018 | 63.8% | +8.5 |
| FY2017 | Dec 31, 2017 | 55.3% | −6.8 |
| FY2016 | Dec 31, 2016 | 62.1% | −21.3 |
| FY2015 | Dec 31, 2015 | 83.4% | +3.9 |
| FY2014 | Dec 31, 2014 | 79.5% | +12.7 |
| FY2013 | Dec 31, 2013 | 66.8% | +11.8 |
| FY2012 | Dec 31, 2012 | 55.0% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 61.6% | +2.6 |
| Q2 FY2026 | Jun 30, 2026 | 62.4% | −2.3 |
| Q1 FY2026 | Mar 31, 2026 | 60.6% | −2.4 |
| Q4 FY2025 | Dec 31, 2025 | 59.4% | +1.5 |
| Q3 FY2025 | Sep 30, 2025 | 59.0% | +1.5 |
| Q2 FY2025 | Jun 30, 2025 | 64.7% | +6.5 |
| Q1 FY2025 | Mar 31, 2025 | 62.9% | −1.3 |
| Q4 FY2024 | Dec 31, 2024 | 57.9% | −1.5 |
| Q3 FY2024 | Sep 30, 2024 | 57.5% | −6.0 |
| Q2 FY2024 | Jun 30, 2024 | 58.2% | −5.5 |
| Q1 FY2024 | Mar 31, 2024 | 64.2% | −0.5 |
| Q4 FY2023 | Dec 31, 2023 | 59.4% | −2.0 |
| Q3 FY2023 | Sep 30, 2023 | 63.5% | +2.8 |
| Q2 FY2023 | Jun 30, 2023 | 63.7% | +11.5 |
| Q1 FY2023 | Mar 31, 2023 | 64.7% | +17.8 |
| Q4 FY2022 | Dec 31, 2022 | 61.5% | +17.1 |
| Q3 FY2022 | Sep 30, 2022 | 60.8% | +7.6 |
| Q2 FY2022 | Jun 30, 2022 | 52.2% | −1.9 |
| Q1 FY2022 | Mar 31, 2022 | 46.8% | −16.5 |
| Q4 FY2021 | Dec 31, 2021 | 44.4% | −12.8 |
| Q3 FY2021 | Sep 30, 2021 | 53.1% | −8.9 |
| Q2 FY2021 | Jun 30, 2021 | 54.1% | −3.2 |
| Q1 FY2021 | Mar 31, 2021 | 63.3% | +7.2 |
| Q4 FY2020 | Dec 31, 2020 | 57.1% | −5.8 |
| Q3 FY2020 | Sep 30, 2020 | 62.0% | −8.8 |
| Q2 FY2020 | Jun 30, 2020 | 57.3% | −13.9 |
| Q1 FY2020 | Mar 31, 2020 | 56.2% | −16.0 |
| Q4 FY2019 | Dec 31, 2019 | 62.9% | −1.9 |
| Q3 FY2019 | Sep 30, 2019 | 70.8% | +1.6 |
| Q2 FY2019 | Jun 30, 2019 | 71.2% | +6.3 |
| Q1 FY2019 | Mar 31, 2019 | 72.2% | +16.7 |
| Q4 FY2018 | Dec 31, 2018 | 64.8% | +8.0 |
| Q3 FY2018 | Sep 30, 2018 | 69.2% | +13.0 |
| Q2 FY2018 | Jun 30, 2018 | 64.9% | +12.1 |
| Q1 FY2018 | Mar 31, 2018 | 55.5% | +0.2 |
| Q4 FY2017 | Dec 31, 2017 | 56.8% | +1.0 |
| Q3 FY2017 | Sep 30, 2017 | 56.2% | – |
| Q2 FY2017 | Jun 30, 2017 | 52.8% | – |
| Q1 FY2017 | Mar 31, 2017 | 55.3% | – |
| Q4 FY2016 | Dec 31, 2016 | 55.7% | – |
See a number that looks wrong?